Adenosine A1Receptor Agonists as Clinically Viable Agents for Treatment of Ischemic Brain Disorders

Annals of the New York Academy of Sciences - United States
doi 10.1111/j.1749-6632.1997.tb48411.x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Is Deep Brain Stimulation a Viable Treatment for Substance-Related Addiction?

Romanian Journal of Neurology/ Revista Romana de Neurologie
Neurology
2019English

Liver X Receptor Agonists as Potential Therapeutic Agents for Dyslipidemia and Atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology
Cardiovascular MedicineCardiology
2003English

Brain Disorders and Its Treatment

Archives in Biomedical Engineering & Biotechnology
2019English

PPARγ Agonists as Therapeutics for the Treatment of Alzheimer’s Disease

Neurotherapeutics
NeurologyPharmacology
2008English

Sex Differences in the Neurotoxic Effects of Adenosine A1Receptor Antagonism During Ethanol Withdrawal: Reversal With an A1Receptor Agonist or an NMDA Receptor Antagonist

Alcoholism: Clinical and Experimental Research
MedicinePsychiatryMental HealthToxicology
2008English

A Functional Screening of Adenosine Analogues at the Adenosine A2BReceptor: A Search for Potent Agonists

Nucleosides and Nucleotides
1998English

Adenosine Receptors as Drug Targets for Treatment of Pulmonary Arterial Hypertension

Frontiers in Pharmacology
Pharmacology
2017English

Are Anti-Inflammatory Therapies Viable Treatments for Psychiatric Disorders?

JAMA Psychiatry
MedicinePsychiatryMental Health
2015English

The Emergence of Thrombopoietin Receptor Agonists as a Novel Treatment for Immune Thrombocytopenia

European Oncology and Haematology
OncologyHematology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy